Echo Therapeutics Announces Issuance of New Patent for Symphony(TM) Transdermal Continuous Glucose Monitoring System

Friday, October 17, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

FRANKLIN, Mass., Oct. 16 Echo Therapeutics (OTC Bulletin Board: ECTE) announced the issuance of U.S. Patent 7,432,069 covering compositions and methods for the preparation of a polyethylene glycol (PEG)-based hydrogel as a key component of Echo's Symphony(TM) Transdermal Continuous Glucose Monitoring (tCGM) System.

"Our proprietary PEG hydrogel, specifically designed to enable transdermal biosensing, is characterized by excellent stability, sensitivity, integrity and biocompatibility, making our Symphony tCGM System a desirable system for non-invasive continuous glucose monitoring," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "This patent is critical to our intellectual property strategy for protecting our leading position in non-invasive, tCGM markets worldwide."

Echo's Symphony(TM) tCGM System is in late-stage development for both the diabetes home use and hospital critical care settings. Symphony incorporates Echo's new Prelude(TM) SkinPrep System with patented, leading-edge skin permeation control technologies.

About Echo Therapeutics

Echo Therapeutics is focused on late-stage development of transdermal diagnostic devices and specialty pharmaceuticals. Echo is developing a non-invasive (needle-free), transdermal continuous glucose monitoring system together with novel transdermal reformulations of existing FDA-approved products.

Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing clinical studies regarding the efficacy of its Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's tCGM System, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic products based on its skin permeation platform technologies, including the Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, and regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System. These and other factors are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-KSB for the year ended December 31, 2007, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. The foregoing list of factors is not exhaustive. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

Investor Relations Contacts: Patrick T. Mooney, M.D. Chairman and CEO Echo Therapeutics 508-530-0329 Melanie Friedman Stern Investor Relations 212-362-1200

SOURCE Echo Therapeutics

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store